Doximity, Inc. (DOCS) vs Iovance Biotherapeutics, Inc. (IOVA)
A side-by-side comparison of Doximity, Inc. and Iovance Biotherapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DOCS
Doximity, Inc.
$28.68HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT
IOVA
Iovance Biotherapeutics, Inc.
$13.33HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT
Total return — DOCS vs IOVA
growth of $100 · dividends reinvested · last 5yDOCS -46.1% (-11.6%/yr)IOVA -45.6% (-11.4%/yr)IOVA compounded faster over this window
DOCS IOVA
DOCS vs IOVA: by the numbers
- •IOVA is the larger company ($5.95B vs $5.36B market cap).
- •DOCS is profitable (25.48% net margin) while IOVA runs a net loss (-89.09%).
Metrics side by side
Valuation
| Metric | DOCS | IOVA |
|---|---|---|
| P/E ratio | 33.74 | N/A |
| Forward P/E | 21.29 | N/A |
| PEG ratio | 0.65 | N/A |
| P/S ratio | 8.18 | 18.31 |
| P/B ratio | 5.86 | 8.08 |
| EV / EBITDA | 24.10 | N/A |
| FCF yield | 5.58% | N/A |
Profitability
| Metric | DOCS | IOVA |
|---|---|---|
| Gross margin | 88.07% | 97.23% |
| Operating margin | 29.60% | -153.08% |
| Net margin | 25.48% | -89.09% |
| ROE | 18.24% | -39.33% |
| ROIC | 15.35% | -37.26% |
Growth (annualized)
| Metric | DOCS | IOVA |
|---|---|---|
| Revenue CAGR (5Y) | 21.94% | N/A |
| EPS CAGR (5Y) | 54.32% | N/A |
| FCF CAGR (5Y) | 23.75% | N/A |
| Total return CAGR (5Y) | -18.23% | -11.55% |
Frequently asked
- Is DOCS or IOVA more profitable?
- DOCS runs the higher net margin — DOCS at 25.48% versus IOVA at -89.09%.
- How have DOCS and IOVA total returns compared?
- Over the past 5 years, DOCS delivered -18.23% and IOVA delivered -11.55% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Doximity P/E ratioDoximity ROEIovance Biotherapeutics ROEDoximity operating marginIovance Biotherapeutics operating marginDoximity revenue growthIovance Biotherapeutics revenue growthDoximity free cash flowIovance Biotherapeutics free cash flow
Doximity & Iovance Biotherapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.